Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Intravenous (IV) vancomycin is used in the treatment of severe infection in neonates. However, its efficacy is compromised by elevated risks of acute kidney injury. The risk is even higher in neonates admitted to the neonatal intensive care unit (NICU) where pharmacokinetics of vancomycin vary widely among neonates. Therapeutic drug monitoring has been an integral part of vancomycin treatment to balance efficacy against toxicity. This involves individual dose adjustments based on observed serum vancomycin concentrations (Cs). However, the existing trough-based approach shows poor evidence for clinical benefits. The updated clinical practice guideline recommends population pharmacokinetic (popPK) model-based approaches, targeting area under curve preferably through the Bayesian approach. Since Bayesian methods cannot be performed manually and require specialized computer programs, there is a compelling need to provide the clinicians with a user-friendly interface to facilitate accurate, personalized dosing recommendations for vancomycin in critically ill neonates. Objective: Utilizing medical data from electronic health records (EHRs) to develop a popPK model and subsequently build a web-based interface to perform model-based individual dose optimization of IV vancomycin for NICU patients in local medical institutions. Methods: Medical data of subjects prescribed with IV vancomycin in the NICU of Prince of Wales Hospital and Queen Elizabeth Hospital in Hong Kong were extracted from EHR sources, namely Clinical Information System, In-Patient Medication Order Entry, and electronic Patient Record. Patient demographics, such as body weight (WT) and postmenstrual age (PMA), serum creatinine (SCr), vancomycin administration records and Cs were collected. The popPK model employed a two-compartment infusion model. Various covariate models were tested against WT, PMA, and SCr , and were evaluated for the best goodness-of-fit. A previously published web-based dosing interface was adapted to develop the interface in this study. Results: The final dataset consisted of EHR data extracted from 207 subjects, with a total of 689 Cs measurements. The final model chosen explains 82% of the variability in vancomycin clearance. All parameter estimates are within the bootstrapping confidence intervals. Predictive plots, residual plots, and visual predictive checks demonstrate good model predictability. Model approximations show that the model-based Bayesian approach consistently promotes the probability of target attainment (PTA) above 75%, while only half of the subjects can achieve PTA over 50% with the trough-based approach. The dosing interface was developed with the capability to optimize individual doses with the model-based empirical or Bayesian approach. Conclusions: Utilizing EHRs, a satisfactory popPK model has been verified and used to develop the web-based individual dose optimization interface. The interface is expected to improve treatment outcomes of IV vancomycin in the treatment of severe infections among critically ill neonates. This study provides the foundation for a cohort study to demonstrate the utility of the new approach compared with previous dosing methods.